CD79A and infection: Our research demonstrated higher production of anti-RBD IgG and IgA in individuals with a history of SARS-CoV-2 infection compared to naïve individuals, during the collection period 4–6 months after the second dose, suggesting that the infection could have potentiated antibody production, especially for individuals in the CoronaVac group.